OBJECTIVE: Owing to the improved long-term outcome after cardiac transplantation, cardiac allograft vasculopathy or valvular disease is developing late after heart transplantation in a growing number of patients. In this study, we evaluated our results of nonretransplant cardiac surgery in these patients and compared them with those after retransplantation. METHODS: Since 1983, a total of 867 heart transplantations have been performed at our institution. Among them, 44 patients underwent nonretransplant cardiac surgery, 4 of them repeatedly. The procedures included 19 coronary artery revascularizations, 20 tricuspid valve procedures, 4 other valvular procedures, 4 aortic operations, and 1 right atrial thrombectomy. Long-term results of these patients were compared with those of 20 patients after late cardiac retransplantation. RESULTS: Indications for nonretransplant surgery included cardiac allograft vasculopathy, tricuspid regurgitation, aortic and mitral valve insufficiency, as well as acute aortic dissection type A. Mean interval between heart transplantation and reoperation was 8.4 years. Mean follow-up was 5.8 years. Early mortality was 4.5% (2/44). The early deaths were caused by intracerebral bleeding and acute rejection. Actuarial survivals at 1, 5, and 7 years were 84%, 64%, and 58%, respectively. In comparison, early mortality in the retransplant group was 20% (4/20) and survivals at the same time points were 70%, 70%, and 47%, respectively. CONCLUSIONS: According to these results, we consider nonretransplant surgical options for cardiac allograft vasculopathy and valvular disease a safe and effective therapeutic approach with low early mortality and acceptable long-term results. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVE: Owing to the improved long-term outcome after cardiac transplantation, cardiac allograft vasculopathy or valvular disease is developing late after heart transplantation in a growing number of patients. In this study, we evaluated our results of nonretransplant cardiac surgery in these patients and compared them with those after retransplantation. METHODS: Since 1983, a total of 867 heart transplantations have been performed at our institution. Among them, 44 patients underwent nonretransplant cardiac surgery, 4 of them repeatedly. The procedures included 19 coronary artery revascularizations, 20 tricuspid valve procedures, 4 other valvular procedures, 4 aortic operations, and 1 right atrial thrombectomy. Long-term results of these patients were compared with those of 20 patients after late cardiac retransplantation. RESULTS: Indications for nonretransplant surgery included cardiac allograft vasculopathy, tricuspid regurgitation, aortic and mitral valve insufficiency, as well as acute aortic dissection type A. Mean interval between heart transplantation and reoperation was 8.4 years. Mean follow-up was 5.8 years. Early mortality was 4.5% (2/44). The early deaths were caused by intracerebral bleeding and acute rejection. Actuarial survivals at 1, 5, and 7 years were 84%, 64%, and 58%, respectively. In comparison, early mortality in the retransplant group was 20% (4/20) and survivals at the same time points were 70%, 70%, and 47%, respectively. CONCLUSIONS: According to these results, we consider nonretransplant surgical options for cardiac allograft vasculopathy and valvular disease a safe and effective therapeutic approach with low early mortality and acceptable long-term results. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: Johannes Gökler; Arezu Z Aliabadi-Zuckermann; Alexandra Kaider; Amrut V Ambardekar; Herwig Antretter; Panagiotis Artemiou; Alejandro M Bertolotti; Udo Boeken; Vicens Brossa; Hannah Copeland; Maria Generosa Crespo-Leiro; Andrea Eixeré-Esteve; Eric Epailly; Mina Farag; Michal Hulman; Kiran K Khush; Marco Masetti; Jignesh Patel; Heather J Ross; Igor Rudež; Scott Silvestry; Sofia Martin Suarez; Amanda Vest; Andreas O Zuckermann Journal: Front Cardiovasc Med Date: 2022-06-09
Authors: Jennie H Kwon; Morgan Hill; Brielle Gerry; Steven W Kubalak; Muhammad Mohiuddin; Minoo N Kavarana; T Konrad Rajab Journal: J Cardiothorac Surg Date: 2021-12-28 Impact factor: 1.637
Authors: Johannes Goekler; Andreas Zuckermann; Emilio Osorio; Faris F Brkic; Keziban Uyanik-Uenal; Guenther Laufer; Arezu Aliabadi-Zuckermann Journal: Transplant Direct Date: 2017-09-09